Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature

Alison Messer, Brandy Drozd, Isabella C. Glitza, Huifang Lu, Anisha B. Patel

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

We present a rare case of dermatomyositis associated with nivolumab therapy for melanoma. Nivolumab is an immune checkpoint inhibitor that blocks the programmed death-1 (PD1) receptor and has a number of associated immunotherapy related adverse events. Although most are T-cell mediated, some are antibody mediated mimics of classical autoimmune diseases. We review the characteristics of other cases of anti-PD1 associated dermatomyositis and the recent literature to better understand how to classify and treat this challenging immunotherapy related adverse event.

Original languageEnglish (US)
Article number4c21b068
JournalDermatology online journal
Volume26
Issue number8
StatePublished - Aug 2020

Keywords

  • Dermatomyositis
  • Immune checkpoint inhibitors
  • Immunotherapy-related adverse events
  • Melanoma
  • Nivolumab
  • PD 1
  • PDL1
  • Pembrolizumab

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature'. Together they form a unique fingerprint.

Cite this